BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46:333-340. [PMID: 15541818 DOI: 10.1016/j.lungcan.2004.05.010] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40:1790-1797. [PMID: 19765801 DOI: 10.1016/j.humpath.2009.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
2 Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21. [PMID: 20564116 DOI: 10.1002/cncr.25196] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
3 Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139. [PMID: 16456816 DOI: 10.1002/cncr.21678] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
4 Hao H, Chen H, Xie L, Liu H, Wang D. LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway. Onco Targets Ther 2021;14:1659-71. [PMID: 33688211 DOI: 10.2147/OTT.S288785] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci. 2008;45:531-562. [PMID: 19003601 DOI: 10.1080/10408360802334743] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 6.4] [Reference Citation Analysis]
6 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Davis CR, Karl J, Granell R, Kirwan JR, Fasham J, Johansen J, Garnero P, Sharif M. Can biochemical markers serve as surrogates for imaging in knee osteoarthritis? Arthritis Rheum 2007;56:4038-47. [PMID: 18050200 DOI: 10.1002/art.23129] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
8 Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71-77. [PMID: 18723551 DOI: 10.1093/annonc/mdn552] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
9 Shantha Kumara HMC, Gaita D, Miyagaki H, Yan X, Hearth SA, Njoh L, Cekic V, Whelan RL. Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection. World J Gastrointest Oncol 2016; 8(8): 607-614 [PMID: 27574553 DOI: 10.4251/wjgo.v8.i8.607] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
10 Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opinion on Therapeutic Targets 2007;11:219-34. [DOI: 10.1517/14728222.11.2.219] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
11 Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP. Circulating glioma biomarkers. Neuro Oncol 2015;17:343-60. [PMID: 25253418 DOI: 10.1093/neuonc/nou207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
12 Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer. 2010;10:593. [PMID: 21029458 DOI: 10.1186/1471-2407-10-593] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
13 Roslind A, Johansen JS, Junker N, Nielsen DL, Dzaferi H, Price PA, Balslev E. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl Immunohistochem Mol Morphol 2007;15:371-81. [PMID: 18091378 DOI: 10.1097/01.pai.0000213146.77772.6a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
14 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 8.0] [Reference Citation Analysis]
15 Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer 2015;137:2696-704. [PMID: 26095694 DOI: 10.1002/ijc.29638] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Park KR, Yun HM, Yoo K, Ham YW, Han SB, Hong JT. Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis. Cell Commun Signal 2020;18:5. [PMID: 32127023 DOI: 10.1186/s12964-019-0503-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
18 Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008;25:801-9. [PMID: 18670741 DOI: 10.1007/s12325-008-0082-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
19 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
20 Hamilton G, Rath B, Ulsperger E. How to target small cell lung cancer. Oncoscience 2015;2:684-92. [PMID: 26425658 DOI: 10.18632/oncoscience.212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Komi DE, Kazemi T, Bussink AP. New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma. Curr Allergy Asthma Rep 2016;16:57. [PMID: 27438466 DOI: 10.1007/s11882-016-0637-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
22 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
23 Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Science 2005;96:183-90. [DOI: 10.1111/j.1349-7006.2005.00026.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
24 Libreros S, Garcia-Areas R, Keating P, Gazaniga N, Robinson P, Humbles A, Iragavarapu-Charyulu VL. Allergen induced pulmonary inflammation enhances mammary tumor growth and metastasis: Role of CHI3L1. J Leukoc Biol 2015;97:929-40. [PMID: 25765679 DOI: 10.1189/jlb.3A0214-114RR] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bjørn ME, Andersen CL, Jensen MK, Hasselbalch HC. Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. Eur J Haematol 2014;93:224-8. [DOI: 10.1111/ejh.12332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
26 Ngernyuang N, Shao R, Suwannarurk K, Limpaiboon T. Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer. Pathology 2018;50:293-7. [PMID: 29452694 DOI: 10.1016/j.pathol.2017.09.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
27 Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene. 2006;25:1242-1250. [PMID: 16247463 DOI: 10.1038/sj.onc.1209141] [Cited by in Crossref: 106] [Cited by in F6Publishing: 108] [Article Influence: 7.1] [Reference Citation Analysis]
28 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
29 Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R, Wiley CA. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008;173:130-43. [PMID: 18556781 DOI: 10.2353/ajpath.2008.080045] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
30 Hempen M, Kopp HP, Elhenicky M, Höbaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009;19:1557-63. [PMID: 19633900 DOI: 10.1007/s11695-009-9917-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
31 Karataş S, Şal V, Kahramanoğlu İ, Demirkıran F, Beşe T, Arvas M, Sofiyeva N, Güralp O, Uzun H. Ykl-40 and cancer antigen 72-4 as new and promising diagnostic and prognostic markers for endometrial cancer. Turk J Obstet Gynecol 2018;15:235-42. [PMID: 30693139 DOI: 10.4274/tjod.77906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hamilton G, Rath B, Burghuber O. Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res 2015;4:287-91. [PMID: 26207216 DOI: 10.3978/j.issn.2218-6751.2015.04.04] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
33 Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M, Ozkan F, Ozkan A. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol. 2008;26:47-52. [PMID: 18190830 DOI: 10.1016/j.urolonc.2007.07.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
34 Qin W, Zhu W, Schlatter L, Miick R, Loy TS, Atasoy U, Hewett JE, Sauter ER. Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int J Cancer 2007;121:1536-42. [PMID: 17565739 DOI: 10.1002/ijc.22881] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
35 Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X, Tamiya T. Association between YKL-40 and adult primary astrocytoma. Cancer 2010;116:2688-97. [PMID: 20499402 DOI: 10.1002/cncr.25084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
36 Liu C, Li Q, Zhou X, Kolosov VP, Perelman JM. The chitinase-like protein YKL-40 increases mucin5AC production in human bronchial epithelial cells. Exp Cell Res 2013;319:2866-73. [PMID: 23994362 DOI: 10.1016/j.yexcr.2013.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
37 Lin HW, Chiang YC, Sun NY, Chen YL, Chang CF, Tai YJ, Chen CA, Cheng WF. CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells. Endocr Relat Cancer 2019;26:73-88. [PMID: 30121622 DOI: 10.1530/ERC-18-0300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Kruit A, Grutters JC, Ruven HJ, van Moorsel CC, van den Bosch JM. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respiratory Medicine 2007;101:1563-71. [DOI: 10.1016/j.rmed.2006.12.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
39 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
40 Abd El-Fattah AA, Sadik NAH, Shaker OG, Mohamed Kamal A. Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk. Mediators Inflamm 2018;2018:9853192. [PMID: 30498395 DOI: 10.1155/2018/9853192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
41 Yang JD, Kim E, Pedersen RA, Kim WR, Pungpapong S, Roberts LR. Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver 2010;4:537-42. [PMID: 21253305 DOI: 10.5009/gnl.2010.4.4.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
42 Weide B, Allgaier N, Hector A, Forschner A, Leiter U, Eigentler TK, Garbe C, Hartl D. Increased CCL17 serum levels are associated with improved survival in advanced melanoma. Cancer Immunol Immunother 2015;64:1075-82. [PMID: 25990074 DOI: 10.1007/s00262-015-1714-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
43 Liu L, Yang Y, Duan H, He J, Sun L, Hu W, Zeng J. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas. Front Oncol 2021;11:611038. [PMID: 33937022 DOI: 10.3389/fonc.2021.611038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Itik V, Kemik O, Kemik A, Dulger AC, Sümer A, Soyoral YU, Begenik H, Purisa S, Kotan C. Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer 2011;3:25-30. [PMID: 24179388 DOI: 10.4137/BIC.S7154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer. 2005;48:223-231. [PMID: 15829322 DOI: 10.1016/j.lungcan.2004.11.011] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
46 Bernardi D, Padoan A, Ballin A, Sartori M, Manara R, Scienza R, Plebani M, Della Puppa A. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol 2012;107:299-305. [PMID: 22102082 DOI: 10.1007/s11060-011-0762-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
47 Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E, Alvarez-Cermeño JC, Villar LM, Tintoré M, Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133:1082-93. [PMID: 20237129 DOI: 10.1093/brain/awq035] [Cited by in Crossref: 184] [Cited by in F6Publishing: 176] [Article Influence: 16.7] [Reference Citation Analysis]
48 Cheray M, Petit D, Forestier L, Karayan-tapon L, Maftah A, Jauberteau M, Battu S, Gallet FP, Lalloué F. Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells. Cancer Letters 2011;312:24-32. [DOI: 10.1016/j.canlet.2011.07.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
49 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
50 Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 2012;48:695-702. [PMID: 21917447 DOI: 10.1016/j.ejca.2011.08.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
51 Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol 2009;9:401-8. [PMID: 19644363 DOI: 10.1097/ACI.0b013e3283306533] [Cited by in Crossref: 72] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
52 Sharif M, Granell R, Johansen J, Clarke S, Elson C, Kirwan JR. Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology 2006;45:522-6. [DOI: 10.1093/rheumatology/kei216] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
53 Kim HR, Jun CD, Lee KS, Cho JH, Jeong ET, Yang SH, Lee YJ, Park DS. Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease. Cytokine 2012;58:336-43. [PMID: 22480951 DOI: 10.1016/j.cyto.2012.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
54 Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-863. [PMID: 17957792 DOI: 10.1002/ijc.23152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
55 Almasi CE, Drivsholm L, Pappot H, Høyer-hansen G, Christensen IJ. The liberated domain I of urokinase plasminogen activator receptor - a new tumour marker in small cell lung cancer. APMIS 2013;121:189-96. [DOI: 10.1111/j.1600-0463.2012.02955.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
56 Tang H, Sun Y, Shi Z, Huang H, Fang Z, Chen J, Xiu Q, Li B. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol. 2013;190:438-446. [PMID: 23197259 DOI: 10.4049/jimmunol.1201827] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 7.4] [Reference Citation Analysis]
57 Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2014;35:277-86. [PMID: 23918300 DOI: 10.1007/s13277-013-1036-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
58 Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 2013;57:99-105. [PMID: 24222276 DOI: 10.1007/s12026-013-8459-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
59 Kim SH, Das K, Noreen S, Coffman F, Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 2007;5:17. [PMID: 17286869 DOI: 10.1186/1477-7819-5-17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
60 Rivas-Alarcón AA, Gómez-Gómez Y, Organista-Nava J, Jiménez-López MA, Rivera-Ramírez AB, Ibarra-Sierra E, Saavedra-Herrera MV, Illades-Aguiar B, Leyva-Vázquez MA. Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia. Mol Clin Oncol 2021;15:168. [PMID: 34194746 DOI: 10.3892/mco.2021.2330] [Reference Citation Analysis]
61 Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435-442. [PMID: 17023034 DOI: 10.1016/j.ygyno.2006.08.028] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
62 Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol. 2006;77:416-424. [PMID: 16930142 DOI: 10.1111/j.0902-4441.2006.t01-1-ejh2879.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
63 Naglot S, Aggarwal P, Dey S, Dalal K. Estimation of Serum YKL-40 by Real-Time Surface Plasmon Resonance Technology in North-Indian Asthma Patients. J Clin Lab Anal 2017;31. [PMID: 27616735 DOI: 10.1002/jcla.22028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Larionova I, Cherdyntseva N, Liu T, Patysheva M, Rakina M, Kzhyshkowska J. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology 2019;8:1596004. [PMID: 31143517 DOI: 10.1080/2162402X.2019.1596004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 39.5] [Reference Citation Analysis]
65 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
66 Adamidi T, Soulitzis N, Neofytou E, Zannetos S, Georgiou A, Benidis K, Papadopoulos A, Siafakas NM, Schiza SE. Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study. BMC Pulm Med 2015;15:150. [PMID: 26620310 DOI: 10.1186/s12890-015-0144-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Park JA, Drazen JM, Tschumperlin DJ. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J Biol Chem 2010;285:29817-25. [PMID: 20650887 DOI: 10.1074/jbc.M110.103416] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
68 Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456-4468. [PMID: 19767768 DOI: 10.1038/onc.2009.292] [Cited by in Crossref: 168] [Cited by in F6Publishing: 179] [Article Influence: 14.0] [Reference Citation Analysis]
69 Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer 2012;106:199-205. [PMID: 22095223 DOI: 10.1038/bjc.2011.501] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
70 Cantó E, Reverter F, Morcillo-suárez C, Matesanz F, Fernández O, Izquierdo G, Vandenbroeck K, Rodríguez-antigüedad A, Urcelay E, Arroyo R, Otaegui D, Olascoaga J, Saiz A, Navarro A, Sanchez A, Domínguez C, Caminero A, Horga A, Tintoré M, Montalban X, Comabella M. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler 2012;18:983-90. [DOI: 10.1177/1352458511433063] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
71 Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol. 2010;49:861-864. [PMID: 20553098 DOI: 10.3109/02841861003631503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
72 Libreros S, Iragavarapu-Charyulu V. YKL-40/CHI3L1 drives inflammation on the road of tumor progression. J Leukoc Biol 2015;98:931-6. [PMID: 26310833 DOI: 10.1189/jlb.3VMR0415-142R] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
73 Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2014;32:663-9. [DOI: 10.1016/j.urolonc.2014.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
74 McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, Brown J, Anderson-Jackson L, Williams L, Latore L, Thompson R, Alexander-Lindo R. Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. Brain Sci 2021;11:215. [PMID: 33578866 DOI: 10.3390/brainsci11020215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
75 Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M, Saygılı U. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol 2016;140:64-9. [PMID: 26607777 DOI: 10.1016/j.ygyno.2015.11.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
76 Pizano-Martínez O, Yañez-Sánchez I, Alatorre-Carranza P, Miranda-Díaz A, Ortiz-Lazareno PC, García-Iglesias T, Daneri-Navarro A, Mercado MVD, Fafutis-Morris M, Delgado-Rizo V. YKL-40 expression in CD14+ liver cells in acute and chronic injury. World J Gastroenterol 2011; 17(33): 3830-3835 [PMID: 21987626 DOI: 10.3748/wjg.v17.i33.3830] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
77 Kacira T, Hanimoglu H, Kucur M, Sanus GZ, Kafadar AM, Tanriverdi T, Kaynar MY. Elevated cerebrospinal fluid and serum YKL-40 levels are not associated with symptomatic vasospasm in patients with aneurysmal subarachnoid haemorrhage. J Clin Neurosci 2008;15:1011-6. [PMID: 18280741 DOI: 10.1016/j.jocn.2006.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
78 Shantha Kumara H, Yan XH, Pettke E, Cekic V, Gandhi ND, Bellini GA, Whelan RL. Plasma and wound fluid levels of eight proangiogenic proteins are elevated after colorectal resection. World J Gastrointest Oncol 2019; 11(6): 470-488 [PMID: 31236198 DOI: 10.4251/wjgo.v11.i6.470] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503-13. [DOI: 10.1002/pros.20311] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
80 Ngernyuang N, Francescone RA, Jearanaikoon P, Daduang J, Supoken A, Yan W, Shao R, Limpaiboon T. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. Int J Biochem Cell Biol 2014;51:45-52. [PMID: 24691276 DOI: 10.1016/j.biocel.2014.03.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
81 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
82 Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011;13:1244-1251. [PMID: 21831900 DOI: 10.1093/neuonc/nor117] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
83 Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H. Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma. JCO 2006;24:798-804. [DOI: 10.1200/jco.2005.03.7960] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
84 Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384. [PMID: 24801872 DOI: 10.1371/journal.pone.0096384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]